A study reports three-year sustained remission with mepolizumab in patients with idiopathic chronic eosinophilic pneumonia. This finding highlights the potential of mepolizumab as a long-term treatment option for this rare eosinophilic disease.
three year sustained remission with mepolizumab in a rare eosinophilic disease idiopathic chronic eosinophilic pneumonia
Original title: “Three-year sustained remission with mepolizumab in a rare eosinophilic disease: idiopathic chronic eosinophilic pneumonia.”